Isozymes in the ciliated protozoan Tetrahymena.

E. B. Meyer,D. Nanney

Abstract:

What problem does this paper attempt to address?

Plasmalogens in human plasma during pregnancy. A study of healthy non-pregnant and pregnant women.

J. Kerstell,A. Svanborg,O. Vikrot

DOI: https://doi.org/10.1111/J.0954-6820.1967.TB07240.X

2009-04-24

Acta Medica Scandinavica

Abstract:
Abstract TP268: Markers of Coagulation and Hemostatic Activation in Ischemic Stroke Patients With Reduced Ejection Fraction on Antiplatelet Therapy

Patrick Glover,Fadi B Nahab

DOI: https://doi.org/10.1161/str.55.suppl_1.tp268

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: Heart failure with reduced ejection fraction (HFrEF) is a risk factor for ischemic stroke. However, antithrombotic choice in a patient with HFrEF remains challenging. We set out to evaluate serum markers of coagulation and hemostatic activation (MOCHA) among ischemic stroke patients with HFrEF. Methods: We performed a retrospective analysis of ischemic stroke patients with HFrEF (<40%) from July 28, 2017-June 13, 2023 seen at the Emory Stroke Clinic who underwent a MOCHA profile (serum D-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, and fibrin monomer) ≥2 weeks after the index stroke; abnormal MOCHA profile was defined as ≥2 elevated markers. We excluded patients who were on anticoagulation therapy at the initial visit. Results: Overall, 40 patients (mean age 60 +/- 13.1, 53% female, 85% nonwhite) met criteria; median EF was 25% (IQR 15%-30%). Frequency of abnormal MOCHA profile was 43% in EF ≥25% and 58% in EF <25% (p = 0.52). No MOCHA components were associated with reduced EF in multivariate linear regression analysis (R2 = 0.03, p = 0.28). Over mean follow-up of 2.3 years, recurrent stroke occurred in 5.3 / 100 patient-years and major adverse cardiac events (MACE) occurred at 7.4 / 100 patient-years. Compared to patients with EF <25%, patients with EF ≥25% had higher recurrent stroke rates (6.46 vs 3.07 per 100 patient-years) and MACE (9.69 and 3.07 per 100 patient-years) Patients on antiplatelet regimens and anticoagulant regimens experienced MACE events at a rate of 4.25 and 10.62 per 100 patient-years, respectively. Patients with abnormal MOCHA profiles (n=20) had no recurrent strokes, but experienced other MACE events at a rate of 3.86 per 100 patient years, while patients with normal MOCHA profiles (n=20) experienced 11.73 MACE events per 100 patient-years, all of which were recurrent strokes. Conclusion: In HFrEF patients with an ischemic stroke, the MOCHA profile was not associated with ejection fraction. No difference in recurrent stroke and MACE events was seen among patients with normal vs abnormal MOCHA profile.

peripheral vascular disease,clinical neurology
Potential Role of 2-Phase Cardiac CT in Patients with Embolic Stroke of Undetermined Source

Shenqiang Yan,Ying Zhou,Quan Han,Yi Chen,Min Lou

DOI: https://doi.org/10.1016/j.amjmed.2019.11.019

2020-01-01

Abstract:-BACKGROUND: Recent trials failed to demonstrate that anticoagulation was superior to antiplatelet agents in preventing recurrent stroke after embolic stroke of undetermined source (ESUS), which may be as a result of the heterogeneity of etiology. We thus investigated whether the use of 2-phase cardiac computed tomography (CT) could help to evaluate the etiology in patients with ESUS. METHODS: We performed 2-phase cardiac CT in patients with ESUS and evaluated whether there was pos-itive cardiac findings. RESULTS: A total of 74 patients with ESUS were enrolled. Positive cardiac findings were found in 21 (28.4%) patients, including intracardiac thrombus (n = 5), complex aortic plaque (n = 9), and patent foramen ovale (PFO) (n = 8). Both complex aortic plaque and patent foramen ovale were identified in 1 patient. CONCLUSIONS: Two-phase cardiac CT is a useful tool for stroke etiology evaluation, providing diagnostic information in a quarter of patients with ESUS. (C) 2019 Elsevier Inc. All rights reserved.
Abstract P558: Identification of Embolic Stroke in Patients with Large Vessel Occlusion

Lan Hong,Longting Lin,Gang Li,Jianhong Yang,Geng Yu,Min Lou,Mark Parsons,Xin Cheng,qiang Dong

DOI: https://doi.org/10.1161/str.52.suppl_1.p558

IF: 10.17

2021-01-01

Stroke

Abstract:Objective: To develop a simple and objective score using clinical variables and quantified perfusion measures to identify embolic stroke with large vessel occlusions. Methods: Eligible patients from the Chinese centers participating in the International Stroke Perfusion Imaging Registry were included in this study. Patients were split into a derivation cohort (n=213) and a validation cohort (n=116). A score was developed according to the coefficients of independent predictors of embolic stroke from stepwise logistic regression model in the derivation cohort. The performance of the score was validated by assessing its discrimination and calibration. Additionally, a comparison between the area under curve (AUC) of history of atrial fibrillation (AF) alone and history of AF plus the score was also conducted. Results: The independent predictors of embolic stroke made up the Chinese Embolic Stroke Score (CHESS). There were: age (≥64 years, 1 point), non-smoking history (1 point), non-hypertension history (1 point) , baseline NIH Stroke Scale (≥14, 1 point) and delay time>6s volume/delay time>3s volume on perfusion imaging (≥0.23, 2 points). The AUC of CHESS in the derivation cohort and validation cohort were 0.80 and 0.72 respectively. Calibration tests indicated high agreement between predicted and observed probabilities. The AUC of AF-plus-CHESS compared to history of AF alone was significant (derivation cohort P<0.001; validation cohort P=0.01). Conclusions: In a Chinese population, CHESS reliably and independently identified embolic stroke as the cause of large vessel occlusion.
Risk and Benefit Evaluation: Application of Multiphase Computed Tomography Angiography in Mechanical Thrombectomy for Patients with Acute Ischemic Stroke.

Xiang Yu,Jingjiang Pan,Xiaoying Zhao,Xianfeng Yu,Bin Liu

DOI: https://doi.org/10.1097/rct.0000000000001219

2021-01-01

Journal of Computer Assisted Tomography

Abstract:Objective The objective of this study was to evaluate the collateral circulation in patients with acute ischemic stroke (AIS) by multiphase computed tomography angiography (mCTA) and explore its application value in the risk and benefit assessment after thrombectomy. Methods Clinical and imaging parameters of AIS patients who underwent thrombectomy were consecutively collected. The 90-day modified Rankin Scale (mRS) score was used as the standard for evaluating the recovery of neurological functions. The receiver operating characteristic curve and correlation analysis were used to evaluate the diagnostic efficacy of collateral circulation in the clinical outcomes at 90 days and the correlation with symptomatic intracerebral hemorrhage (sICH), respectively. Results Thirty of 58 AIS patients (51.7%) had favorable functional recovery (90-day mRS score, ≤2). Significant differences were observed in age, time from symptom onset to groin puncture, National Institutes of Health Stroke Scale score at admission and 24 hours after thrombectomy, mRS score at discharge, collateral circulation score, and target mismatch between the favorable and unfavorable groups (P < 0.05). The diagnostic efficacy of mCTA collateral score (area under the curve, 0.697; 95% confidence interval, 0.563–0.831) was similar to that of computed tomography perfusion target mismatch (area under the curve, 0.740; 95% confidence interval, 0.609–0.872) (DeLong test, P = 0.575). The collateral circulation score was significantly negatively correlated with sICH (ρ = −0.607, P < 0.001). Patients with sICH had lower collateral circulation scores and higher 90-day mRS scores (P < 0.05). Conclusions The mCTA collateral score has good application value in the risk and benefit evaluation after mechanical thrombectomy, and it is well suited for routine emergency assessment of AIS patients.
RNA epigenetics.

Nian Liu,T. Pan

DOI: https://doi.org/10.1016/j.trsl.2014.04.003

Abstract:
New Perspective on the Risk Markers for Left Atrial Thrombosis in Patients with Atrial Fibrillation.

Xuan Zhang,Mengjie Hu,Xiying Wang,Chi Zhang,Wanwan Chen,Songzan Chen,Jintao Zhou,Yuxiao Chen,Lian Lou,Guoping Chen,Fanghong Dong,Shenjiang Hu,Liangrong Zheng,Jian Yang

DOI: https://doi.org/10.1177/2047487320912084

IF: 8.526

2020-01-01

European Journal of Preventive Cardiology

Abstract:BACKGROUND:Anticoagulant therapy is one of the important aspects of atrial fibrillation (AF) management, which can effectively reduce the formation of left atrial thrombosis (LAT) and the occurrence of embolic events. The CHA2DS2-VASc score is a commonly used risk assessment tool for embolic events, and it has guiding significance for anticoagulant therapy. However, a large number of recent studies have clearly shown that some of the markers that are not included in the score affect the formation of LAT.OBJECTIVE:This single-center study probed for risk markers for LAT by analyzing the clinical features of patients who experienced AF.METHODS:We reviewed patients with AF who had undergone a transesophageal echocardiography exam over the past 6 years and used binary logistic regression analysis to identify risk markers other than CHA2DS2-VASc score. For the risk markers found, the propensity score matching (PSM) was used to further evaluate whether it was an independent risk marker for LAT. The newly discovered markers were added to the score, and receiver operating characteristic analysis was used to evaluate whether the ability of the model to predict LAT was improved.RESULTS:A total of 2246 patients were included in the study. In total, 838 of them were anticoagulated (314 with rivaroxaban, 57 with dabigatran, and 467 with warfarin) and 30 patients (1.33%) had LAT. Regression analysis revealed abnormal uric acid metabolism (abUA) and obesity were risk markers for LAT. Further PSM analysis found that abUA was an independent risk marker for LAT. After including abUA, the CHA2DS2-VASc score was more accurate for LAT prediction (area under the curve difference is 0.0651, 95% confidence interval: 0.0247, 0.1050, Z = 3.158, P = 0.0016).CONCLUSIONS:AbUA is an independent risk marker for LAT. After considering abUA, the CHA2DS2-VASc score for LAT is more accurate.
Abstract TP150: Magnetic Resonance Imaging Predictors of Atrial Fibrillation in Cryptogenic Stroke Cases

Keshv K Srinivasan,Lisa A Davis,Adrienne N Dula,

DOI: https://doi.org/10.1161/str.55.suppl_1.tp150

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: Ischemic stroke is a leading cause of death and disability in the US, with 20-40% of cases, classified as cryptogenic or with an unexplained cause. Detection of one cause, paroxysmal atrial fibrillation (AF), is critical to ensuring optimal treatment with direct oral anticoagulant (DOAC). Currently, the most reliable AF detection strategy is use of an insertable cardiac monitor (ICM). However, earlier detection of occult cardioembolic patterns using MRI may promote earlier decisions for DOAC use. The overall goal of this study is to determine if MRI lesion patterns are predictive of AF detection by ICM. Methodology: Cases of consecutive patients (1/1/2015 - 12/31/2017) with MRI-confirmed stroke performed 48h from time last known well and prior to endovascular treatment were retrospectively analyzed. The primary outcome, presence of occult atrial fibrillation, was detected by ICM placement within 90 days and follow-up within 180 days from stroke. Four imaging patterns were tested as predictors of AF: i) acute stroke lesion involving multiple vascular territories (MVT, i.e. right or left carotid and/or posterior circulation), ii) MVT plus wedge-shaped cortical infarct or chronic stroke on FLAIR, iii) MVT involving 3 territories, and iv) MVT in 3 territories plus chronic FLAIR lesion. Adjustment variables were based on univariate logistic regression predictors of AF at P ≤0.1000. Results: Of the 101 cases in this analysis, the median age was 63 years and 49.5% male. Stroke in multiple vascular territories MVT was present in 22/101 (22%) at baseline. The total AF 6-month detection rate was 36/101 (36%). The imaging pattern most predictive of AF was pattern ii, MVT plus chronic FLAIR with an unadjusted odds ratio (OR) of 3.47, 95% CI of 0.3442-2.1731, P=.0073. The adjusted OR (age ≥ 55, history of stroke, and history of TIA,) was 3.26, 95% CI: 1.0358-11.1860, P =.0480. Conclusion: The presence of acute lesions in MVT and a chronic FLAIR lesion may be a biomarker of occult cardioembolic source that could be used early after the onset of stroke to determine optimal DOAC use for secondary prevention and potential risk reduction of stroke recurrence from suspected but unproven cardioembolic source. Funding: Lone Star Stroke Research Consortium

peripheral vascular disease,clinical neurology
Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC

George Ntaios,Helmut Baumgartner,Wolfram Doehner,Erwan Donal,Thor Edvardsen,Jeff S Healey,Bernard Iung,Hooman Kamel,Scott E Kasner,Eleni Korompoki,Babak B Navi,Christian Pristipino,Luca Saba,Renate B Schnabel,Emma Svennberg,Gregory Y H Lip

DOI: https://doi.org/10.1093/eurheartj/ehae150

IF: 39.3

2024-05-01

European Heart Journal

Abstract:One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause amongst a list of potential differential diagnoses, in order to optimize secondary prevention. However, specifically in ESUS, this may be challenging as multiple potential thromboembolic sources frequently coexist. Also, it can be delusively reassuring because despite the implementation of specific treatments for the individual pathology presumed to be the actual thromboembolic source, patients can still be vulnerable to stroke and other cardiovascular events caused by other pathologies already identified during the index diagnostic evaluation but whose thromboembolic potential was underestimated. Therefore, rather than trying to presume which particular mechanism is the actual embolic source in an ESUS patient, it is important to assess the overall thromboembolic risk of the patient through synthesis of the individual risks linked to all pathologies present, regardless if presumed causally associated or not. In this paper, a multi-disciplinary panel of clinicians/researchers from various backgrounds of expertise and specialties (cardiology, internal medicine, neurology, radiology and vascular surgery) proposes a comprehensive multi-dimensional assessment of the overall thromboembolic risk in ESUS patients through the composition of individual risks associated with all prevalent pathologies.

cardiac & cardiovascular systems
Markers of Atrial Cardiopathy in Severe Embolic Strokes of Undetermined Source

Maurizio Acampa,Alessandra Cartocci,Carlo Domenichelli,Rossana Tassi,Francesca Guideri,Pietro Enea Lazzerini,Giuseppe Martini

DOI: https://doi.org/10.3389/fcvm.2022.903778

2022-06-20

Abstract:Background and purpose: The current definition of embolic strokes of undetermined source (ESUS) seems to be too broad, including strokes due to heterogeneous mechanisms, such as atrial cardiopathy and other occult cardiac conditions, aortic arch plaques, and non-stenosing atherosclerosis, that can be differently associated with clinical stroke severity at the time of presentation. The aim of our study was to assess the possible association between neurological deficit severity and presence of markers of atrial cardiopathy in ESUS. Methods: We retrospectively reviewed the medical records of a cohort of 226 ESUS patients (105 M, 121 F), that were divided into two groups according to the severity of neurological deficit (99 mild strokes with NIHSS ≤ 5 and 127 severe strokes with NIHSS >5). The following indices of atrial cardiopathy were evaluated: P wave dispersion, P wave max, P wave min, P wave mean, P wave index, P wave axis, left atrial size. Results: Patients with severe ESUS were significantly older (74 ± 12 vs. 67 ± 14 years, P < 0.001) and female sex was prevalent (67 vs. 36%, P > 0.001); they had higher values of P-wave-dispersion (51 ± 14 vs. 46 ± 13, P = 0.01), P-wave-max (131 ± 20 vs. 125 ± 15 ms, P = 0.01), P-wave-index (16 ± 5 vs. 15 ± 5 ms, P = 0.01), left atrial size (20 ± 6 vs. 18 ± 4 cm2, P = 0.01), left atrial volume index (31 ± 14 vs. 27 ± 11 ml/m2, P = 0.04), in comparison with mild ESUS. An abnormal P wave axis was detected more frequently in severe ESUS (21 vs. 9%, P = 0.01). Furthermore, multivariate logistic regression showed that age (OR = 1.21 for each 5-year increase, 95% CI 1.09-1.35), sex (OR = 3.24 for female sex, 95% CI 1.82-5.76) and PWD (OR = 1.32 for each 10-ms increase, 95% CI 1.07-1.64) were the best subset of associated variables for severe ESUS. Conclusions: Our findings shed light on specific clinical characteristics of severe ESUS including the presence of atrial cardiopathy that could play a pathogenic role in this subgroup of patients. Searching for atrial fibrillation in these patients is especially important to perform the most appropriate therapy.
Atrial Cardiomyopathy: An Emerging Cause of the Embolic Stroke of Undetermined Source

Yuye Ning,Gary Tse,Guogang Luo,Guoliang Li

DOI: https://doi.org/10.3389/fcvm.2021.674612

IF: 3.6

2021-08-09

Frontiers in Cardiovascular Medicine

Abstract:Nearly 30% of ischemic strokes have an unknown cause, which are referred to as cryptogenic strokes (CS). Imaging studies suggest that a large proportion of these patients show features that are consistent with embolism, and thus the term embolic stroke of undetermined source (ESUS) was proposed to describe these CS patients. Atrial cardiomyopathy predisposes to thrombus formation and thus embolic stroke even in the absence of atrial fibrillation (AF). This may provide a mechanistic link with ESUS, suggesting that anticoagulant therapy may be more beneficial than antiplatelet therapy in ESUS patients with atrial cardiomyopathy. The present review discusses the concept of atrial cardiomyopathy and ESUS and the relationship between them based on the mechanisms and clinical evidence, suggests that atrial cardiomyopathy may be a potential mechanism of ESUS, and highlights a theoretical basis that supports that anticoagulant therapy may be more applicable to ESUS patients with atrial cardiomyopathy and aims to help us better understand and identify the risk of ESUS, thereby improving the management of these patients in clinical practice.

cardiac & cardiovascular systems
Embolic stroke of undetermined source: Focusing on atrial cardiopathy and patent foramen ovale

Meng Zhang,Qi Xiao,Kun Wang,Ruihua Yin,Guangzhen Liu,Hongqin Zhao,Peng Li,Xiaoyan Zhu,Xudong Pan

DOI: https://doi.org/10.1016/j.ijcard.2024.131810

IF: 4.039

2024-01-25

International Journal of Cardiology

Abstract:Background Atrial cardiopathy(AC) and patent foramen ovale (PFO) are two etiologies of embolic strokes of undetermined source (ESUS). We aimed to explore the relationship between them in ESUS. Methods A total of 1146 participants were included from January 2019 to June 2022, which included the ESUS group and non-embolic stroke which includes LAA(large arterial atherosclerosis) + SAO(small artery occlusion) group. AC was defined as the presence of at least one of the following: PTFV1(P-wave terminal force in lead V1) > 4000 μV*ms in the electrocardiograms, NT-proBNP(N-terminal probrain natriuretic peptide) > 250 pg/mL in laboratory tests or LAD(left atrial diameter) > 3.8 cm for women and > 4.0 cm for men in cardiac ultrasound. The presence of PFO was assessed by transthoracic echocardiography, transcranial Doppler ultrasound, transesophageal echocardiography or cardiac MRI. PFO was considered pathogenic if the RoPE score was 7 to 10. Results The prevalence of AC and PFO was higher in the ESUS group than the LAA + SAO group. The prevalence of AC was lower in ESUS patients with pathogenic PFO (37.9%) than those without PFO (68.4%) and with incidental PFO (64.0%) ( p = 0.006). The prevalence of pathogenic PFO was lower in ESUS patients with AC than those without AC (6.0% vs. 17.8%, p = 0.006). The AUC(area under the curve) of PTFV1 for predicting ESUS was 0.724 [95%CI (0.686–0.762), p < 0.05)], indicating that PTFV1 the most valuable AC biomarker. Conclusions The prevalence of AC is inversely related to the prevalence of pathogenic PFO in ESUS patients. PTFV1 was the most valuable index to predict ESUS among the AC biomarkers.

cardiac & cardiovascular systems
Hypercoagulability Existing in the Local Left Atrium of Patient with Mitral Stenosis

JA Wang,XY Xie,H He,JW Huang,D Lu,Q Yang

IF: 6.133

2003-01-01

Chinese Medical Journal

Abstract:OBJECTIVE:To investigate the pathogenesis of thromboembolism in patients with mitral stenosis in a pre-thrombotic state. METHODS:The biochemical markers' levels in plasma for platelet activity [soluble P-selectin (GMP-140)], states of thrombin generation [antithrombin III (AT III) and protein C (PC)], fibrinolysis [D-dimer (DD), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA) and FDP] and von Willebrand factor (vWF) were determined from blood specimens obtained from the femoral veins and arteries and the right and left atria of 43 consecutive patients (20 with atrial fibrillation and 23 with sinus rhythm) with mitral stenosis (MS), undergoing percutaneous mitral valvuloplasty. The same parameters were compared with those of 15 control subjects, who had no detectable heart disease, but with paroxysmal supraventricular tachycardia undergoing radiofrequency catheter ablation of the left accessory pathway through a transseptal passage. RESULTS:Blood from the left atrium contained an excessive amount of platelet activity, thrombin generation and fibrinolysis compared with the blood from the right atrium, and the femoral veins and arteries. However blood from the right atrium was much lower in these activities when compared with those from the left atrium, and the femoral veins and arteries in both groups. Compared with those in the control subjects, GMP-140 in the left atrium was significantly higher (P < 0.05) and AT III was significantly lower (P < 0.05) in patients with MS. Compared with the patients with MS and spontaneous left atrial echocontrast (LASEC) = 1, the patients with MS and LASEC >/= 2 had significantly higher levels of GMP-140 in plasma (P < 0.05), and significantly lower levels of AT III (P < 0.05) and PC (P < 0.01) levels in the left atrium. However, there were no significant differences between patients with atrial fibrillation and those with sinus rhythm regarding amounts of plasma coagulation markers in the left atrium. Univariate regression analysis revealed that LASEC was negatively correlated with plasma levels of blood from the left atria in the patients with MS. CONCLUSION:Coagulability is increased in the left atria of patients with MS and is positively correlated with LASEC.
Atherothrombotic and thrombolytic biomarkers in incident stroke and atrial fibrillation-related stroke: The Multi-Ethnic Study of Atherosclerosis (MESA)

Karita Claudia Freitas Lidani,Patrick James Trainor,Harpreet S. Bhatia,Khurram Nasir,Michael J. Blaha,Michael Y. Tsai,Rebecca F. Gottesman,Wendy S. Post,George Thanassoulis,Sotirios Tsimikas,Susan R. Heckbert,Andrew Paul DeFilippis

DOI: https://doi.org/10.1016/j.atherosclerosis.2024.117451

IF: 5.3

2024-01-12

Atherosclerosis

Abstract:Background and aims Although several biomarkers have been studied in thromboembolic stroke, measuring the balance between thrombus formation and thrombolysis and its role in predicting stroke and atrial fibrillation (AF)-related stroke is limited. We sought to assess atherothrombotic biomarkers grouped into composite factors that reflect thrombotic and thrombolytic potential, and the balance between these factors as it relates to incident stroke or transient ischemic attack (TIA) and stroke/TIA in AF. Methods A Thrombotic Factor , derived from fibrinogen, plasmin–antiplasmin complex, factor VIII, D-dimer, and lipoprotein(a); and a Thrombolytic Factor , derived from plasminogen and oxidized phospholipids on plasminogen, were evaluated at baseline in 5,764 Multi-Ethnic Study of Atherosclerosis (MESA) participants. We evaluated the association between these two factors representative of thrombotic and thrombolytic potential and incident stroke/TIA (n = 402), and AF-related stroke/TIA (n = 82) over a median of 13.9 and 3.7 years, respectively. Cox proportional hazard models adjusted for medication use, cardiovascular risk factors and CHA 2 DS 2 -VASc score were utilized. Harrell's C-index was estimated to evaluate model performance. Results In models including both factors, Thrombotic Factor was positively while Thrombolytic Factor was inversely associated with incident stroke/TIA and AF-related stroke/TIA. Incorporating these factors along with the CHA 2 DS 2 -VASc in adjusted models resulted in a small improvement in risk prediction of incident stroke/TIA and AF-related stroke/TIA compared to models without the factors (C-index from 0.697 to 0.704, and from 0.657 to 0.675, respectively). Conclusions Composite biomarker factors, representative of the balance between thrombotic and thrombolytic propensity, provided an improvement in predicting stroke/TIA beyond CHA 2 DS 2 -VASc score.

cardiac & cardiovascular systems,peripheral vascular disease
Overview and Future Direction of Embolic Stroke of Undetermined Source from the Insights of CHALLENGE ESUS/CS Registry

Muneaki Kikuno,Yuji Ueno

DOI: https://doi.org/10.5551/jat.RV22026

2024-09-27

Abstract:Cryptogenic stroke (CS) accounts for approximately one-fourth of acute ischemic strokes, with most cases derived from embolic etiologies. In 2014, embolic stroke of undetermined source (ESUS) was advocated and the efficacy of anticoagulant therapy was anticipated. However, 3 large-scale clinical trials failed to demonstrate the superiority of direct oral anticoagulants (DOACs) over aspirin, potentially due to the heterogeneous and diverse pathologies of ESUS, including paroxysmal atrial fibrillation (AF), arteriogenic sources such as nonstenotic carotid plaque and aortic complicated lesion (ACL), patent foramen oval (PFO), and nonbacterial thrombotic endocarditis (NBTE) related to active cancer.Transesophageal echocardiography (TEE) is one of the most effective imaging modalities for assessing embolic sources in ESUS and CS. The Mechanisms of Embolic Stroke Clarified by Transesophageal Echocardiography for Embolic Stroke of Undetermined Source/Cryptogenic Stroke (CHALLENGE ESUS/CS) registry is a multicenter registry that enrolled consecutive patients with CS who underwent TEE at 8 hospitals in Japan between April 2014 and December 2016. Their mean age was 68.7±12.8 years, and 455 patients (67.2%) were male. The median National Institutes of Health Stroke Scale (NIHSS) score was 2. Since 7 analyses have been conducted from each institution to date, novel and significant insights regarding embolic origins and pathophysiologies of ESUS and CS were elucidated from this multicenter registry. This review discusses the diagnosis and treatment of ESUS and CS, tracing their past and future directions. Meaningful insights from the CHALLENGE ESUS/CS registry are also referenced and analyzed.
Abstract WP128: Using Clinical Data to Reclassify ESUS Patients to Either Large Artery Atherosclerotic or Cardioembolic Stroke Mechanisms

Lauren R Klein,David L Tirschwell,Daniel Hippe,Brooke Haines,Niranjan Balu,Thomas S Hatsukami,Chun Yuan,Mona Kharaji,Nazem W Akoum,Eardi Lila,Mahmud Mossa-basha

DOI: https://doi.org/10.1161/str.55.suppl_1.wp128

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: Defining the specific underlying pathophysiology of ischemic stroke is critical for minimizing the risk of recurrent events with personalized secondary prevention treatments. A notable portion of ischemic strokes are classified as embolic stroke of undetermined source (ESUS), leaving these patients without optimal treatment tailored to their pathophysiology. Hypothesis: Standard clinically collected data can reliably reclassify a substantial portion of ESUS patients into either a large artery atherosclerotic (LAA) or cardioembolic (CE) cause. Methods: A statistical model was developed to discriminate LAA from CE using a retrospective cohort of ischemic stroke patients treated at the University of Washington. A total of 189 patients were included (79 CE and 61 LAA to train the model, 49 ESUS patients to assess reclassification). Sixteen candidate predictors were collected across several sources: clinical risk factors, blood tests, echocardiography, ECG, and neurovascular imaging (Table 1). The LASSO (least absolute shrinkage and selection operator) was used to select important predictors in a penalized logistic regression model with stroke etiology (LAA vs. CE) as the outcome. ESUS patients were considered reclassified if the model-based probability of CE or LAA was at least 75%. Results: Of 189 patients, the mean (SD) age was 68 (14) years and 40% were women. The LASSO selected 12 predictors to discriminate CE vs. LAA (Table 1), with a corresponding cross-validated C-statistic = 0.87 (95% CI: 0.82-0.94). When the model was applied to the 49 ESUS patients, 23 (47%) were reclassified to LAA and 6 (12%) to CE. Conclusions: A multivariate model based on standard clinical data can separate LAA from CE with a high degree of discrimination. Applying this model led to reclassification to either LAA or CE in 59% of ESUS patients. Such approaches may enable more personalized secondary prevention strategies, but need to be tested in future trials.

peripheral vascular disease,clinical neurology
MicroRNA Expression Profiles Identify Biomarker for Differentiating the Embolic Stroke from Thrombotic Stroke.

Lai-Te Chen,Chen-Yang Jiang

DOI: https://doi.org/10.1155/2018/4514178

2018-01-01

BioMed Research International

Abstract:In order to identify potential biomarkers that distinguish the embolic stroke (ES) from thrombotic stroke (TS), a profile of microRNA expression was analyzed. The GSE60319 expression profile was downloaded from the Gene Expression Omnibus (GEO) database. The GEO2R was applied to screen for differentially expressed microRNAs (DEmiRNAs) between the embolic stroke group and thrombotic stroke group. The miRWalk was utilized to predict the target genes of DEmiRNAs. Genes associated with embolic stroke were downloaded from the Comparative Toxicogenomics Database. Cross reference of target genes to disease related genes was conducted to construct the DEmiRNA-gene network. The protein-protein interaction (PPI) network of overlapping genes was evaluated by STRING, using the MCODE and CytoHubba plugin of Cytoscape to identify the modules and hub genes. The enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) in modules was performed. There were 30 microRNAs in total identified as DEmiRNAs between embolic stroke and thrombotic stroke groups, of which 8 were upregulated and 22 were downregulated. Among these differentially expressed miRNAs, miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were significantly associated with an ES to TS. Using the miRWalk 3.0 online tool, target genes regulated by DEmiRNAs were predicted. In addition, disease related genes were predicted and compared with target genes of DEmiRNAs. 166 overlapped genes regulated by miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were identified, suggesting their association with diseases that contributed to ES, mainly including atrial fibrillation, mitral valve stenosis, myocardial infarction, and aortic dissection. Therefore, miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were promising candidate biomarkers for differentiating an ES from TS. The PPI network demonstrated that miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were associated with an ES by mainly regulating "CCND1, E2F2, E2F3, ITCH, UBE4A, UBE3C, RBL2, FBXO31, EIF2C4, and EIF2C1". Furthermore, miR-15a-5p and miR-17-5p may function through "cell cycle, prostate cancer, and small cell lung cancer" while miR-19b-3p and miR-20a-5p function through "insulin resistance, hepatitis B, and viral carcinogenesis" and "vasopressin-regulated water reabsorption", respectively. However, these results were approached in the manner of bioinformatics analysis; therefore, further verification is required.
Abstract TP223: Predicting Atrial Fibrillation in Embolic Stroke of Unknown Source

Hassan O Aboul-Nour,Yi Ge,S M Shafiul Hasan,Xiao Hu,Fadi B Nahab

DOI: https://doi.org/10.1161/str.55.suppl_1.tp223

IF: 10.17

2024-02-01

Stroke

Abstract:Background: A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrial fibrillation (AF). Studies have shown that prolonged outpatient cardiac monitoring increases the chances of AF detection and impacts choice of antithrombotic therapy. The Brown ESUS-AF Score, a prediction tool utilizing age and left atrial enlargement has previously shown promise in predicting AF in ESUS patients. In this study we aimed to externally validate the Brown ESUS-AF score and compare its performance against a random forest classifier. Methods: We included all patients with ESUS who underwent an inpatient stroke evaluation followed by outpatient cardiac monitoring between October 9,2015-March 31,2023. To validate the Brown ESUS-AF score, our cohort was divided between those who developed AF during follow-up versus those who did not. To develop the random forest classifier, we included demographics, medical comorbidities, lab records, echocardiographic and electrocardiographic findings. We did 80/20 train-test split to fine tune the model, and we identified features that had the greatest performance contribution. Results: Of 468 patients, 97(20.7%) patients had occult AF. AF patients were older(68.6±13.0 vs 60.1±15.6;p=0.0001), had a higher left atrial (LA) volume index(30.6±12.3 vs 26.2±10.0;p=0.0001) and larger LA diameter(3.8 ± 0.7 vs 3.5 ± 0.7;p=0.002) compared to those who did not develop AF. We found that a Brown ESUS-AF score of≥2 had lower sensitivity in our patient cohort than the original development cohort (42%vs63%). In comparing our random forest classifier to the Brown ESUS-AF score, our model had higher c-statistic (0.71vs0.64). The most important features we identified are age, LAVI, PR and QT Interval, triglyceride level and platelets. Conclusion: Our machine learning model incorporating 52 variables performed better than the Brown ESUS-AF score in predicting AF in our large and diverse ESUS cohort.

peripheral vascular disease,clinical neurology
Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B‐cell survival

A. Ruiz,Jie Jiang,H. Kempski,H. Brady

DOI: https://doi.org/10.1111/j.1365-2141.2004.04854.x

2004-04-01

British Journal of Haematology

Abstract:The Ikaros transcription factor has been shown to play an important role in the differentiation of both myeloid and lymphoid lineages. Mice heterozygous for a dominant negative (DN) ikaros isoform develop T‐cell leukaemia and lymphoma with 100% penetrance. Overexpression of DN Ikaros isoforms has been reported in some forms of leukaemia, such as childhood acute myelomonocytic and monocytic leukaemias, adult B‐cell acute lymphoblastic leukaemias (B ALL) and in childhood and adult pre‐B ALL. In this study, the expression of Ikaros isoforms in 49 infant and childhood leukaemia patients was analysed by reverse transcription polymerase chain reaction and Western blot analysis. We found overexpression of the DN Ikaros 6 (Ik6) isoform in a subset of leukaemia patients harbouring t(4;11) translocations. To further study the consequences of Ik6 overexpression in B ALL, we inducibly expressed Ik6 in BaF3 cells and found that Ik6 overexpression delayed cell death after interleukin‐3 withdrawal, suggesting that overexpression of Ik6 found in t(4;11) B cells could contribute to leukaemogenesis by preventing the apoptosis of cells in an environment with reduced survival factors.
Abstract TP276: AF Detection on Zio-Patch is Higher in ESUS vs. Non-Cardioembolic Stroke Subtype

Jason Chang,Liqi Shu,Eric Goldstein,Karen L Furie,Shadi Yaghi

DOI: https://doi.org/10.1161/str.55.suppl_1.tp276

IF: 10.17

2024-02-01

Stroke

Abstract:Background: Clinical trials showed that the paroxysmal occult AF is detected in 30% of patients with cryptogenic stroke on insertable cardiac monitors but recently the STROKE-AF trial showed a similar rate in patients with non-cardioembolic stroke, thus questioning the significance of device detected AF as a cause of the ischemic stroke. In this study, we aim to compare AF detection rates in patients with ESUS compared to those with non-cardieombolic stroke mechanisms on ZIOPATCH monitoring. Methods: We analyzed data of patients with acute ischemic stroke who had a two-week ZIOPATCH monitor placed post stroke over a 2 year period. We collected data on demographics, risk factors, and ZIOPATCH findings in all patients. Stroke subtype was categorized based on the TOAST criteria into small vessel disease, large artery atherosclerosis, stroke of other determined mechanism, and cryptogenic stroke. Cryptogenic stroke was defined based on the ESUS criteria. AF was abstracted from the ZIOPATCH report and confirmed by the reviewing physician. We determined association between stroke subtype (ESUS versus non-cardioembolic stroke) and AF detection using multivariable models. Results: Over the study period, we identified 239 patients discharged with a diagnosis of acute ischemic stroke who underwent cardiac monitoring via a 2-week ZIOPATCH with a median of 13 days of monitoring; 116 (49%) were ESUS and 65 (27%) were classified as large artery atherosclerosis and 19% were classified as small vessel disease. AF was detected 3.3% (8/239) of patients. In univariate analyses, patients with ESUS were more likely to have AF compared to non-cardieombolic stroke (6.0% vs. 0.8%, p = 0.032). In an adjusted model controlling for age, patients with ESUS were more likely to have AF detected on ZIOPATCH (aOR 7.53, p = 0.06). Conclusions: Paroxysmal occult AF detected on a 2-week ZIOPATCH is more likely to occur in ESUS vs. non-cardioembolic suggesting a mechanistic association with cardioembolism.

peripheral vascular disease,clinical neurology

Isozymes in the ciliated protozoan Tetrahymena.

Plasmalogens in human plasma during pregnancy. A study of healthy non-pregnant and pregnant women.

Abstract TP268: Markers of Coagulation and Hemostatic Activation in Ischemic Stroke Patients With Reduced Ejection Fraction on Antiplatelet Therapy

Potential Role of 2-Phase Cardiac CT in Patients with Embolic Stroke of Undetermined Source

Abstract P558: Identification of Embolic Stroke in Patients with Large Vessel Occlusion

Risk and Benefit Evaluation: Application of Multiphase Computed Tomography Angiography in Mechanical Thrombectomy for Patients with Acute Ischemic Stroke.

RNA epigenetics.

New Perspective on the Risk Markers for Left Atrial Thrombosis in Patients with Atrial Fibrillation.

Abstract TP150: Magnetic Resonance Imaging Predictors of Atrial Fibrillation in Cryptogenic Stroke Cases

Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC

Markers of Atrial Cardiopathy in Severe Embolic Strokes of Undetermined Source

Atrial Cardiomyopathy: An Emerging Cause of the Embolic Stroke of Undetermined Source

Embolic stroke of undetermined source: Focusing on atrial cardiopathy and patent foramen ovale

Hypercoagulability Existing in the Local Left Atrium of Patient with Mitral Stenosis

Atherothrombotic and thrombolytic biomarkers in incident stroke and atrial fibrillation-related stroke: The Multi-Ethnic Study of Atherosclerosis (MESA)

Overview and Future Direction of Embolic Stroke of Undetermined Source from the Insights of CHALLENGE ESUS/CS Registry

Abstract WP128: Using Clinical Data to Reclassify ESUS Patients to Either Large Artery Atherosclerotic or Cardioembolic Stroke Mechanisms

MicroRNA Expression Profiles Identify Biomarker for Differentiating the Embolic Stroke from Thrombotic Stroke.

Abstract TP223: Predicting Atrial Fibrillation in Embolic Stroke of Unknown Source

Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B‐cell survival

Abstract TP276: AF Detection on Zio-Patch is Higher in ESUS vs. Non-Cardioembolic Stroke Subtype